I had lab work done 5/12/26 including STR for chimerism. Initial result indicated that my CD34+ decreased from 86%...

Understanding Your CD34+ Chimerism Results After Allo-HSCT

Thank you for sharing this important lab result. I can help you understand what this finding means in the context of your allogeneic hematopoietic stem cell transplant (allo-HSCT) for your transplant-associated MDS (tMDS).

What CD34+ Chimerism Means

CD34+ cells are hematopoietic stem cells — the "parent" cells in your bone marrow that give rise to all your blood cells. When chimerism testing measures CD34+, it's specifically looking at whether these stem cells are coming from your donor (donor chimerism) or from your own cells (recipient chimerism).

Your result shows:

• CD34+ decreased from 86% to 0% — This means the percentage of your own CD34+ stem cells has dropped to essentially undetectable levels
• This suggests increasing donor chimerism in the stem cell compartment (meaning more of your stem cells are now coming from your donor)

Is This Concerning?

The short answer: This finding requires context from your complete chimerism panel, and your transplant team is the right source for interpretation.

Here's why this matters:

What Generally Indicates Good Engraftment:

According to NCCN Guidelines for Myelodysplastic Syndromes, successful allo-HSCT typically shows:

• Increasing donor chimerism over time (which your CD34+ result suggests)
• Full donor chimerism in myeloid lineages (neutrophils, monocytes) — this is the most clinically important
• Mixed or full chimerism in lymphoid lineages (T cells, B cells) — varies by protocol

Your CD34+ moving toward 0% recipient chimerism could actually indicate successful donor engraftment — the donor's stem cells are taking over, which is the goal.

Why You Need the Complete Panel:

The other lineages you're waiting for are critical:

• Myeloid chimerism (CD33+, CD13+) — most important for predicting relapse risk
• T-cell chimerism (CD3+, CD8+) — you had CD8 tested in February; this relates to graft-versus-leukemia effect and graft-versus-host disease (GVHD) risk
• B-cell chimerism (CD19+) — indicates immune reconstitution

Full myeloid donor chimerism with mixed T-cell chimerism is often the ideal pattern — it suggests good disease control with lower GVHD risk.

---

Questions to Ask Your Transplant Team

Since you're waiting for your complete chimerism results, here are specific questions that will help you understand the full picture:

1. "Is the CD34+ result consistent with successful engraftment, or does it suggest a concerning pattern?" (They'll have your complete dataset)

2. "What are my myeloid and T-cell chimerism percentages, and what do they indicate about my transplant status?"

3. "Given my IPSS-M moderate-low risk MDS and TP53-negative status, what chimerism pattern are you targeting?" (Your baseline risk profile matters for interpretation)

4. "Are there any signs of mixed chimerism that might require intervention, such as donor lymphocyte infusion (DLI)?"

5. "How does this chimerism result relate to my recent mouth sores and other symptoms I've been experiencing?" (This could indicate GVHD or other post-transplant complications)

---

Important Context: Your Timeline

You're now 15 months post-allo-HSCT for tMDS. At this timepoint:

• Chimerism should be relatively stable (major shifts typically occur in the first 3-6 months)
• Full donor chimerism is the goal for disease control
• Persistent mixed chimerism might warrant discussion of DLI or other interventions
• Recurrent recipient chimerism would be concerning for relapse risk

According to NCCN MDS Guidelines, chimerism monitoring is standard post-transplant surveillance, and your team uses these results to assess:

• Engraftment success
• Relapse risk
• Need for additional interventions

---

Why This Matters for Your MDS

Your specific situation:

• TP53 mutation-negative (favorable prognostic marker)
• IPSS-M moderate-low risk (lower relapse risk than high-risk MDS)
• 15 months post-transplant (in the window where chimerism patterns stabilize)

These factors suggest your transplant team may have more flexibility in managing chimerism patterns compared to higher-risk patients.

---

Bottom Line

A CD34+ result moving toward full donor chimerism is often a positive sign, but the complete picture requires:

• Your myeloid lineage chimerism (most important)
• Your T-cell chimerism results
• Your transplant team's interpretation in context of your clinical status

Don't wait passively for results — reach out to your transplant team and ask them to explain the complete chimerism panel once it's available. This is exactly the kind of detailed question they expect and can answer with your full clinical picture.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.